Using Mendelian randomization to determine causative factors in cardiovascular disease

Journal of Internal Medicine

Volumn 273, Issue 1, 2013, Pages 44-47

  Johansen, C T ^a   Hegele, R A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CONCENTRATION (PARAMETERS); DISEASE COURSE; EDITORIAL; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; GLUCURONOSYLTRANSFERASE; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; MORBIDITY;

EID: 84871705238     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02586.x     Document Type: Editorial

References (27)

1. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-6.
2. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007; 43: 1-57.
3. Fischman D, Valluri A, Gorrepati VS, Murphy ME, Peters I, Cheriyath P. Bilirubin as a Protective Factor for Rheumatoid Arthritis: an NHANES Study of 2003-2006 Data. J Clin Med Res 2010; 2: 256-60.
4. Chang Y, Ryu S, Zhang Y et al. A cohort study of serum bilirubin levels and incident non-alcoholic Fatty liver disease in middle aged korean workers. PLoS ONE 2011; 7: e37241.
5. Cheriyath P, Gorrepati VS, Peters I et al. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1999-2006. J Clin Med Res 2010; 2: 201-6.
6. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008; 198: 1-11.
7. Vitek L, Jirsa M, Brodanova M et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160: 449-56.
8. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med 2012: doi: 10.1111/j.1365-2796.2012.02576.x
9. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22.
10. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008; 5: e177.
11. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27: 1133-63.
12. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; 1: 507-8.
13. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120: 833-43.
14. Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634-9.
15. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9.
16. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-28.
17. Elliott P, Chambers JC, Zhang W et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302: 37-48.
18. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-908.
19. Edmondson AC, Brown RJ, Kathiresan S et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009; 119: 1042-50.
20. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54, 500 individuals. J Clin Endocrinol Metab 2012; 97: E248-56.
21. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572-80.
22. Strassburg CP. Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? Drug Metab Rev 2010; 42: 168-81.
23. Evans AS. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med 1976; 49: 175-95.
24. Hill AB. The Environment and Disease: association or Causation? Proc R Soc Med 1965; 58: 295-300.
25. Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008; 199: 390-6.
26. Boon AC, Hawkins CL, Bisht K et al. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 2012; 52: 2120-7.
27. Tapan S, Karadurmus N, Dogru T et al. Decreased small dense LDL levels in Gilbert's syndrome. Clin Biochem 2011; 44: 300-3.